Breast Cancer Therapy Market – By Diagnostic Procedures , By Stages of Breast Cancer , By Age Group , By Therapy Type , By End User , By Geography - Opportunity Analysis & Industry Forecast, 2024-2030

Breast Cancer Therapy Market Overview:

The Breast Cancer Therapy Market size is estimated to reach $59 billion by 2030, growing at a CAGR of 9.1% during the forecast period 2024-2030. The rising incidence of breast cancer globally is a key driver of the breast cancer therapy market. The demand for effective and target treatments is increasing as more women are being diagnosed. Early diagnosis is becoming possible due to technological advances, such as MRI, PET scans, and BRCA1/BRCA2 genetic testing which are important for improving survival rates for patients. Along with these advances, there has also been enhancement in targeted treatments, including HER 2 inhibitors, CDK4/6 inhibitors and immunotherapies which result in increasing survivability of patients. These therapies work to address the genetic genomes of patients in an unprecedented manner, all the while reducing side effects that come with traditional chemotherapy treatments. 

Further, additional research, development investments are driving the discovery of new therapies and biosimilars that will help further expand the treatment horizon for the breast cancer patients. Similarly, promoting early detection by government and health organizations is playing an important role through public awareness campaigns and subsidizes access to treatment leading to increase demand for breast cancer therapies. Such initiatives play a major role in reducing mortality rates, and enabling patients to receive timely effective treatment that ultimately contributes to market growth.

Market Snapshot: 

Breast Cancer Therapy Market - Report Coverage:

The “Breast Cancer Therapy Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Breast Cancer Therapy Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The COVID-19 pandemic disrupted the breast cancer therapy market by delaying diagnosis and treatments due to lockdowns and overwhelmed healthcare systems. Late-stage diagnosis of the disease occurred because of reduced patient visits. Medicines and even essential devices, were supplied by the market in limited quantities disrupting the flow of essential medication supply slowing down demand and slowing growth.
• The Russia-Ukraine war has significantly strained global healthcare resources, with funds increasingly diverted toward emergency and military needs. This shift has left critical sectors like breast cancer research and advanced treatment options underfunded. As countries prioritize defense budgets to ensure national security, healthcare investments have suffered, resulting in delayed advancements and limited access to innovative therapies. Consequently, patients face restricted options for cutting-edge treatments, posing serious implications for long-term healthcare progress in fields requiring intensive research, like oncology.

Key Takeaways:

North America Region is the Leading Region

North America accounted for the largest market share of Breast Cancer Therapy Market in 2023. The breast cancer therapy market is led by North America, reflecting the high count of breast cancer cases especially within the United States. Breastcancer.org reports that breast cancer is the most common cancer for women, accounting for 30 % of new cancer diagnoses among women in the U.S. In 2024, it is expected that around 310,720 women will be diagnosed with invasive breast cancer, with 16% of these cases occurring in women under the age of 50. Furthermore, approximately 56,500 women will be diagnosed with ductal carcinoma in situ (DCIS). The large patient population is accompanied by a developed healthcare system making space for quick adoption of newly developed therapeutics. The region's market dominance is also dependent on ongoing research in breast cancer treatment. Early detection is also facilitated by widespread awareness and the existence of routine screening programs, and the consequent increased demand for better treatment options.

Chemotherapy Leads the Market

Chemotherapy dominates the Breast Cancer Therapy Market due to its wide usage in breast cancer treatment, drug categories such as anthracyclines, taxanes, and platinum-based drugs are included in chemotherapy and is broadly used for reducing tumor size, preventing recurrence, and treating metastatic breast cancer. Medical News Today reports that chemotherapy is the most commonly used treatment in breast cancer, specifically when used combined with surgery or radiotherapy. Where 82% of stage 3 patients and 66% of stage 4 patients undergo Chemotherapy for removal, and Radiotherapy. Moreover, in stage 1 and 2 patients, about 2% of patients receive breast-conserving surgey (BCS) with chemotherapy, and. 17% undergo BCS combined with both radiotherapy and chemotherapy. The wide usage of Chemotherapy through all the stages and the ability of Chemotherapy to be used combinedly with other therapies to cure breast cancer makes it the most commonly used therapy in the Breast Cancer Therapy Market.

Mammography is the Largest Segment 

Mammography is the most commonly used diagnostic procedure to detect breast cancer due to its reliability and efficiency. The National Cancer Institute reports that mammography has a success rate of 90% in detecting breast cancer which makes it a reliable method for diagnosis. The wide usage of mammography is due to its ability to detect breast cancer in the early stages, mostly before the symptoms develop, making it a critical tool in increasing survival rates and improving treatment. The National Cancer Institute further states that 90% of women who go through mammography for diagnosis receive accurate negative results. The ability to detect early signs of breast cancer and widely acceptance for its contribution to reduce breast cancer has made it a routine healthcare for women. These factors combined, underpin why mammography is the most commonly used diagnostic method for detecting breast cancer in the Breast Cancer Therapy Market.

Technological Advancements in Detection 

Technological advancements are a major driver in the breast cancer therapy market due to their role in improving detection and treatment methods. New and more advanced technologies such as digital mammography and computer aided detection (CAD) devices allow increased imaging accuracy in uncovering cancers that are often missed, reports WebMD. Other developments like 3D ultrasound and MRI, which give detailed, non-invasive pictures of breast tissue are further increasing early detection. For example, two experimental techniques such as positron emission tomography (PET) and near infrared (NIR) spectral imaging appear to help identify tumors earlier, according to WebMS. This describes that these advancements are not only improving diagnostic accuracy but that they’re also offering more comfort and convenience for the patient, which cuts down on the discomfort with traditional screening methods. These technologies are driving the demand for more effective and personalized breast cancer therapies by enhancing detection and minimizing false positives. 

Expensive Cancer Therapy

High costs in breast cancer therapy present a significant challenge, particularly as these expenses can place advanced treatment options out of reach for many patients. In India, for instance, the average cost of breast cancer treatment is approximately INR 7,00,000, with more intensive treatments reaching up to INR 16,50,000 according to Denvax. This steep price range, covering surgery, chemotherapy, radiation, and ongoing medical care, burdens patients and their families, who may struggle to afford comprehensive care. As a result, many patients face difficult choices between optimal treatments and financial stability. This financial strain is compounded by limited insurance coverage, especially for newer therapies that may not be fully reimbursed. Additionally, the high cost of research and development for targeted therapies and immunotherapy has driven up treatment prices. Consequently, the issue of affordability continues to hinder equitable access to effective breast cancer treatment, limiting the ability of healthcare systems to reduce breast cancer mortality rates and improve patient outcomes.

For more details on this report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Breast Cancer Therapy Market. The top 10 companies in this industry are listed below:

1. F.Hoffmann-La Roche Ltd
2. Novartis AG
3. AstraZeneca
4. Pfizer Inc.
5. Eli Lilly and Company
6. Bristol Myers Squibb (BMS)
7. Merck & Co., Inc.
8. Amgen Inc.
9. Celgene
10. AbbVie

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here